Introduction {#s1}
============

Synaptic plasticity is central to memory and other adaptive responses of adult neural circuits. NMDA receptor (NMDAR)-dependent long-term potentiation (LTP) and long-term depression (LTD) are triggered by the activation of NMDARs but expressed by an increase or decrease in the abundance of AMPA receptors (AMPARs) at the postsynaptic membrane, respectively. Postsynaptic LTD induced by the activation of group I metabotropic glutamate receptors (mGluR-LTD) is similarly expressed by a reduction in the number of postsynaptic AMPARs (Luscher and Huber, [@B56]). AMPARs are tetrameric complexes composed of GluA1, GluA2, GluA3, or GluA4 subunits, with GluA1/2 heteromers dominant at hippocampal CA1 synapses. The number and composition of postsynaptic AMPARs are in a dynamic balance, which is achieved by AMPAR trafficking. AMPAR trafficking involves intracellular transport, endo-/exo-cytosis, recycling, lateral surface diffusion, and degradation (Choquet, [@B14]). Newly synthesized receptors are transported intracellularly on microtubules from soma to dendrites. Through exocytosis/endocytosis, AMPARs cycle between intracellular and surface pools. Recycling refers to the process by which endocytosed receptors are returned to the cell surface *via* exocytosis. Surface AMPARs exchange between synaptic and extrasynaptic compartments *via* lateral diffusion and are reversibly trapped at synapses by postsynaptic scaffold proteins, cytoskeletal proteins, adhesion proteins, or extracellular matrix. This continuous exchange of receptors between different pools establishes a dynamic equilibrium ([Figure 1](#F1){ref-type="fig"}, top panel). This balance can be shifted in response to neuronal/synaptic activity (Opazo and Choquet, [@B71]). For example, during LTP, AMPARs are selectively recruited, by lateral diffusion, to the postsynaptic membrane to increase synaptic strength, while exocytosed AMPARs serve as an extrasynaptic reservoir (Makino and Malinow, [@B61]; Penn et al., [@B75]). Conversely, during LTD, AMPARs are dispersed, through endocytosis, from the postsynaptic membrane to reduce synaptic transmission. Thus, synaptic strength at single synapses is bidirectionally regulated *via* AMPAR trafficking.

![AMPAR trafficking under physiological and pathological conditions and AMPAR-based therapeutic strategies. **Top panel**, basal condition. AMPARs constitutively cycle between intracellular pools and the neuronal surface *via* endocytosis and exocytosis. At the plasma membrane, AMPARs bidirectionally exchange between extrasynaptic and synaptic compartments by lateral diffusion, powered by thermal agitation. This is readily perturbed by protein-protein interactions at postsynaptic sites, where AMPARs are trapped by reversible binding to postsynaptic density (PSD) proteins, cytoskeletal proteins, adhesion proteins, or extracellular matrix. The dynamic equilibrium established between different pools allows the steady state levels of AMPARs at synapses. **Bottom left panel**, pathological conditions, such as addiction, stress/depression, chronic pain, and epilepsy. The equilibrium is shifted towards the accumulation of postsynaptic AMPARs in a region/circuit-specific and subunit-specific manner. This may be due to the enhanced diffusion trapping mechanisms and/or potentiated exocytosis (Red). AMPAR lateral diffusion mediates the recruitment of extrasynaptic AMPARs to the postsynaptic membrane. AMPAR-based therapeutic strategies, which ameliorate drug-seeking behavior, chronic pain, or epileptic seizures in corresponding animal models, include reducing diffusion trapping and/or enhancing endocytosis (such as with optogenetic LTD induction or mGluR1 positive allosteric modulator), or inhibiting AMPAR-mediated currents by AMPAR antagonists. **Bottom right panel**, pathological conditions, such as Huntington's disease (HD), Alzheimer's disease (AD), Parkinson's disease (PD), and fragile X syndrome (FXS). The equilibrium is shifted towards the dispersal of AMPARs from the postsynaptic membrane in hippocampal and cortical neurons, which is linked to cognitive deficits, likely through the impairment of diffusion trapping mechanisms resulting in an increase in AMPAR lateral diffusion, potentiation of endocytosis, and/or suppression of exocytosis (Red). AMPAR-based therapeutic strategies, which improve synaptic plasticity and/or memory in animal models of HD, AD and FXS, include enhancing diffusion trapping mechanisms (such as with tianeptine), blocking endocytosis (such as with mGluR5 antagonists), or enhancing AMPAR function (such as with AMPAR positive allosteric modulators)(Blue). However, the effects of these strategies in human patients remain to be determined. Brain region- and AMPAR subunit-specific treatment is needed.](fnsyn-12-00026-g0001){#F1}

Increasing evidence shows that learning and memory can be modified at the cellular and molecular levels by acute modulation of LTP, LTD, or AMPAR trafficking. For example, fear memory established by associating a foot-shock with optogenetic stimulation of auditory inputs to the amygdala was inactivated by subsequent optogenetic delivery of LTD to the conditioned auditory input and further reactivated by optogenetic delivery of LTP (Nabavi et al., [@B70]). Moreover, PhotonSABER, an optogenetic tool developed to inhibit AMPAR endocytosis during LTD in a light-dependent manner, was applied in Purkinje cells and inhibited cerebellar motor learning (Kakegawa et al., [@B38]). Furthermore, immobilization of surface AMPARs by crosslinking approaches markedly impaired hippocampal LTP *in vivo* and also inhibited contextual fear conditioning (Penn et al., [@B75]). These results support a causal contribution of AMPAR trafficking and synaptic plasticity to learning and memory. Second, they suggest that learning and memory can be manipulated at the molecular level (AMPARs trafficking), as well as at the cellular level by induction of LTP or LTD.

Notably, the dynamic equilibrium of AMPAR trafficking can also be shifted under pathological conditions ([Figure 1](#F1){ref-type="fig"}, bottom left and bottom right panels). Increasing evidence suggests that brain region-specific and AMPAR subunit-specific aberrant enhancement or reduction in synaptic transmission or plasticity occurs with many neurodegenerative, neurodevelopmental, and neuropsychiatric disorders. A reversal of these aberrations ameliorates drug-seeking behavior, chronic pain, epileptic seizures, or cognitive deficits. Although the etiology, pathogenesis, and symptoms vary greatly between disorders, the observed restoration of function and mitigation of symptoms suggest that dysregulation of AMPAR-mediated synaptic transmission and plasticity is a convergence point for multiple pathological pathways, rather than a compensatory protective mechanism.

Below, we review the evidence of brain region-specific and AMPAR subunit-specific bidirectional dysregulation of AMAPR-mediated synaptic transmission and plasticity in animal models of several of the most common neurodegenerative, neurodevelopmental and neuropsychiatric disorders. We also review the therapeutic effects exerted by targeting AMPAR subunits or trafficking. We propose that, despite the highly diverse underlying pathologies, dysregulation of AMPARs is a common mechanism in the expression of different diseases, and bidirectional therapeutic targeting of AMPARs may be a promising mitigation strategy for various diseases. Lastly, we discuss the potential therapeutic application of small interfering peptides and aptamers, as well as the need for new optogenetic and optopharmacological tools for elucidating the molecular mechanisms and spatial-temporal dynamics of AMPA regulation in animal models of brain disorders.

Addiction {#s1-1}
---------

Addiction is a psychological and physical inability to stop consuming a chemical, despite adverse consequences. Many addictive drugs induce changes in the synaptic composition of AMPARs and alter synaptic plasticity within reward circuitry, such as the ventral tegmental area (VTA), nucleus accumbens (NAc), prefrontal cortex (PFC), dorsal medial striatum (DMS), and amygdala (Ungless et al., [@B94]; Saal et al., [@B78]; Wolf, [@B102]; Cooper et al., [@B16]). These drugs include cocaine (Conrad et al., [@B15]), delta(9)-tetrahydrocannabinol (Good and Lupica, [@B26]), methamphetamine (Scheyer et al., [@B81]), amphetamine (Saal et al., [@B78]), benzodiazepines (Tan et al., [@B90]), nicotine (Marchi et al., [@B63]), morphine (Madayag et al., [@B59]), heroin (Van den Oever et al., [@B95]), and alcohol (Ma et al., [@B57]). For instance, cocaine exposure or self-administration induced silent synapses, which do not contain AMPARs but only NMDARs, in NAc (Ma et al., [@B58]; Huang et al., [@B34]). However, extended withdrawal (e.g., 30--45 days) from cocaine self-administration resulted in the unsilencing of synapses *via* the synaptic insertion of Ca^2+^-permeable (CP) GluA2-lacking AMPARs. This indicated that CP-AMPARs do not primarily mediate drug-seeking *per se*, but rather contribute to withdrawal-dependent enhancement (incubation) of cocaine-seeking behavior (Conrad et al., [@B15]; Lee et al., [@B47]; Ma et al., [@B58]; Scheyer et al., [@B81]). Optogenetically induced LTD resulting in CP-AMPAR removal from amygdala-to-NAc synapses attenuated incubation of cocaine craving (Lee et al., [@B47]). Besides, the application of a mGluR1 positive allosteric modulator, by removing CP-AMPARs from NAc synapses, also reduced the expression of incubated cocaine craving (Loweth et al., [@B55]). Further evidence suggested that, depending on the input pathway, synaptic insertion of non-CP-AMPARs also underlies cocaine-seeking behavior. In one study, extended cocaine withdrawal evoked the insertion of CP-AMPARs in NAc synapses receiving input from medial PFC, whereas non-CP-AMPARs were inserted at synapses with input from the ventral hippocampus. Optogenetic reversal of plasticity at both inputs abolished cocaine seeking (Pascoli et al., [@B74]). In another study, extended cocaine withdrawal induced CP-AMPAR insertion in NAc synapses with infralimbic (IL) mPFC input, whereas non-CP-AMPARs were inserted at synapses with prelimbic (PrL) mPFC input. Optogenetic reversal of the plasticity of IL-to-NAc and PrL- to-NAc projections enhanced and reduced, respectively, incubation of cocaine craving (Ma et al., [@B58]), suggesting a circuit-dependent mechanism. Moreover, optogenetic LTP and LTD induction at projections from mPFC to DMS increased and decreased alcohol-seeking behavior, respectively (Ma et al., [@B57]). Furthermore, microinjection of NASPM, a synthetic analog of Joro spider toxin that selectively inhibits homomeric GluA1-AMPARs (CP-AMPARs), into the central nucleus of the amygdala, reduced morphine intake of rats (Hou et al., [@B30]).

Clathrin- and GluA2-dependent AMPAR endocytosis appears to play a crucial role in D-amphetamine-induced behavioral sensitization (Brebner et al., [@B8]; Choi et al., [@B13]), morphine-induced place preference (Dias et al., [@B19]) and cue-induced reinstatement of heroin self-administration (Van den Oever et al., [@B95]). Blocking regulated AMPAR endocytosis and LTD by GluA2-derived peptide (Tat-GluA2~3Y~) prevented the expression and maintenance of D-amphetamine-induced behavioral sensitization (Brebner et al., [@B8]; Choi et al., [@B13]), facilitated the extinction of morphine-induced conditioned place preference (Dias et al., [@B19]), and reduced heroin seeking (Van den Oever et al., [@B95]). Collectively, these results suggest a critical role for AMPAR trafficking and AMPAR-mediated plasticity in addictive behavior. Targeting AMPAR subunits or AMPAR trafficking may represent a therapeutic strategy for addiction.

Stress/Depression {#s1-2}
-----------------

Stress in humans is defined as bodily or mental tension caused by physical, mental, or emotional factors.

Stressor exposure promotes the release of hormones from the adrenal gland, such as corticosterone, epinephrine, and norepinephrine (NE). The effect of stress on AMPAR synaptic plasticity is complex and region-specific (McGrath and Briand, [@B65]). For example, the administration of corticosterone to hippocampal neuronal cultures resulted in time-dependent synaptic accumulation of GluA2-AMPARs, possibly by increasing GluA2-AMPAR surface diffusion (Groc et al., [@B27]). The regulation of AMPARs was biphasic, with mineralocorticoid receptors (MRs) and glucocorticoid receptors (GRs) mediating early (minutes) and late (hours) responses to corticosterone, respectively. The MR-dependent increase in synaptic AMPAR contents facilitated chemical LTP induction, while the GR-dependent increase occluded chemical LTP (Groc et al., [@B27]; Krugers et al., [@B44]). This reflected a saturation process of LTP and also provided a cellular mechanism for the finding that short bath application of corticosterone (100 nM, 5--10 min) to hippocampal slices enhanced the frequency of AMPAR miniature excitatory postsynaptic potentials (mEPSC) in CA1 pyramidal neurons *via* MRs (Karst et al., [@B40]), while within hours, corticosterone slowly increased the amplitude of AMPAR mEPSC through GRs (Karst and Joëls, [@B41]) and impaired synaptic potentiation (Kim and Diamond, [@B43]; Zhang et al., [@B105]). Notably, the antidepressant tianeptine reversed the corticosterone-induced increase in AMPAR surface diffusion in hippocampal neurons and restored hippocampal LTP in slices from acutely stressed mice (Zhang et al., [@B105]). This suggests that reversal of AMPAR surface trafficking may contribute to the restoration of hippocampal synaptic plasticity in animal models of stress. Other stressful stimuli, such as NE and emotional stress, induced the phosphorylation and synaptic delivery of GluA1-AMPARs in hippocampal slice cultures, which was thought to lower the threshold for LTP (Hu et al., [@B33]). It is noteworthy that social defeat stress was shown to reduce the levels of GluA1-AMPAR in the PFC and hippocampus, but elevate its levels in NAc (Yang et al., [@B104]). Furthermore, stress paradigms that impair hippocampal LTP have been found to facilitate amygdala LTP (Vouimba et al., [@B96]; Suvrathan et al., [@B87]). This implies that there may be important region-specific differences in AMPAR regulation and plasticity that need to be taken into account in the development of therapeutics.

Interestingly, increasing evidence suggests that stress facilitates the development of drug addiction. This may be attributed, at least in part, to stress-induced changes in synaptic plasticity (Lo Iacono et al., [@B53]; McGrath and Briand, [@B65]). Indeed, drugs of abuse and stress trigger common plasticity mechanisms in midbrain dopamine neurons. Acute stress and *in vivo* administration of drugs of abuse with different molecular mechanisms both enhanced the AMPAR/NMDAR EPSC ratio at excitatory synapses onto midbrain dopaminergic neurons (Saal et al., [@B78]). Another study found that early stressors such as repeated maternal separation increased TNF levels in the PFC and NAc while reducing GluA2 levels in male but not female rats. Maternally separated male rats display a greater preference for a cocaine-associated context, which was reversed by the TNF inhibitor XPro 1595 through normalizing TNF and GluA2 levels (Ganguly et al., [@B24]). Notably, chronic stress in humans is associated with higher rates of depression or depressive episodes (Kendler et al., [@B42]). Thus, the implications of these findings might extend to depression.

Chronic Pain {#s1-3}
------------

Chronic pain conditions often have a psychological component in the form of a persistent sensory memory of the pain state, associated with fear, anxiety, and cognitive dysfunction. LTP and LTD in the dorsal horn of the spinal cord and cortical areas, including the anterior cingulate cortex (ACC), are increasingly thought to underlie chronic pain (Bliss et al., [@B5]). In particular, evidence from genetic and pharmacological studies indicates that the recruitment of GluA1-AMPARs to the postsynaptic membrane contributes to the expression of NMDAR-dependent LTP in the ACC (Toyoda et al., [@B92], [@B93]; Xu et al., [@B103]; Li et al., [@B49]), the pathogenesis of chronic inflammation and neuropathic pain (Xu et al., [@B103]; Li et al., [@B49]), and chronic visceral pain (Liu et al., [@B52]; Wang et al., [@B100]). Analgesic effects were obtained by inhibiting AMPAR-mediated responses or reducing the expression of postsynaptic LTP in the ACC (Li et al., [@B49]; Chen et al., [@B11]; Liu et al., [@B52]; Wang et al., [@B100]; Zhuo, [@B111]).

Epilepsy {#s1-4}
--------

Epilepsy is a neurological disorder characterized by recurrent and unprovoked seizures, reflecting episodic abnormal synchronized electrical activity in cerebral neuronal networks (Rogawski, [@B77]). Imbalanced excitatory and inhibitory synaptic transmission is thought to contribute to epilepsy pathogenesis (Bonansco and Fuenzalida, [@B7]). An elevation of hippocampal AMPAR levels has been reported in both temporal lobe epilepsy (TLE) patients and several animal epilepsy models (Mathern et al., [@B64]; Lopes et al., [@B54]). This is supported by a positron emission tomography (PET) tracer study of AMPARs (\[11C\]K-2), showing that \[11C\]K-2 uptake is increased in the epileptogenic focus of patients with mesial TLE (Miyazaki et al., [@B67]). Therapeutic strategies inhibiting AMPA-mediated currents, e.g., AMPAR antagonists, have been developed to treat epilepsy. AMPAR antagonists have been shown to alleviate epileptiform activity in *in vitro* models and confer protection from seizures in many animal seizure models (Rogawski, [@B77]). In particular, a selective non-competitive AMPAR antagonist, perampanel, has been clinically used to treat patients with partial-onset and tonic-clonic seizures (French et al., [@B22],[@B23]; Piña-Garza et al., [@B76]).

Summary of Addiction, Stress, Chronic Pain, and Epilepsy Models {#s1-5}
---------------------------------------------------------------

Taken together, the available data suggest that region- and subunit-specific pathological potentiation of AMPAR-mediated synaptic transmission is a common feature of animal models of addiction, stress, chronic pain, and epilepsy models ([Figure 1](#F1){ref-type="fig"}, bottom left panel). In these models, experimental inhibition of potentiated AMPAR-mediated transmission, eg. using AMPAR antagonists or reversal of enhanced synaptic strength by regulating AMPAR trafficking and redistribution was able to mitigate addictive behavior, chronic pain, and epileptic seizures. In contrast, in the following sections, we review a set of disorders that are characterized by an impaired LTP or enhanced LTD, which has been associated with cognitive deficits.

Huntington's Disease (HD) {#s1-6}
-------------------------

Huntington's disease (HD) is an autosomal dominant inherited neurodegenerative disease, clinically characterized by cognitive deficits, psychiatric disturbance, and motor dysfunction. HD is caused by a mutated form of the huntingtin gene and the resulting mutant huntingtin protein (Saudou and Humbert, [@B80]). Increasing evidence suggests that cognitive and psychiatric disturbances occur in HD gene carriers and HD mouse models well before classical neuropathology or the onset of motor symptom, suggesting that the initial development of the disease results from a cellular dysfunction rather than a loss of neurons (Lemiere et al., [@B48]; Solomon et al., [@B86]). Various transgenic and knock-in HD mouse models exhibit impaired hippocampal LTP at the pre- or early-symptomatic stage (Hodgson et al., [@B29]; Murphy et al., [@B69]; Zhang et al., [@B106]). Consistently, behavioral studies reveal the deterioration of hippocampal-associated spatial memory in distinct HD murine models and patients (Chan et al., [@B10]; Majerová et al., [@B60]). Recent work has shown that AMPAR surface diffusion is dramatically increased in hippocampal neurons from HD rodent models. This was attributed to deficient brain-derived neurotrophic factor (BDNF)--Tropomyosin related kinase B (TrkB) signaling, which disrupted AMPAR diffusion trapping, i.e., the interaction between transmembrane AMPA receptor regulatory proteins (TARPs) and the PDZ-domain scaffold protein PSD95 (Zhang et al., [@B106]). The antidepressant tianeptine improved BDNF synthesis and intracellular transport, reversed AMPAR surface diffusion, and restored LTP and hippocampus-dependent memory in different HD mouse models (Zhang et al., [@B106]). AMPAR positive allosteric modulators (AMPAkines) have also been shown to rescue the deficits in synaptic plasticity and memory in HD mouse models, possibly via upregulating BDNF (Simmons et al., [@B112], [@B113]).

Alzheimer's Disease (AD) {#s1-7}
------------------------

Alzheimer's disease (AD) is a progressive neurodegenerative disease, clinically characterized by early memory deficits and progressive loss of higher cognitive functions. The causes of AD are unclear, but amyloid-β protein (Aβ) and tau are thought to play a central role in the etiology and pathogenesis. Extracellular amyloid plaques (composed of Aβ peptides) and intraneuronal neurofibrillary tangles (composed of tau) are pathological hallmarks of AD (Bloom, [@B6]). However, increasing evidence suggests that AD begins with synaptic failure before overt neuronal degeneration, which may contribute to the early memory impairments (Selkoe, [@B82]; Luscher and Huber, [@B56]; Opazo et al., [@B72]).

Impaired NMDAR-dependent hippocampal LTP or enhanced LTD are observed in various transgenic AD animal models (Mango et al., [@B62]). Tau protein appears to be involved in synaptic removal of AMPARs, as clustering of tau fibrils reduced synaptic abundance of AMPARs (Shrivastava et al., [@B85]). Moreover, Tau protein phosphorylation was involved in a ketamine-induced reduction in surface expression of AMPARs in hippocampal neurons (Li et al., [@B50]). Besides, mGluR-LTD induced by soluble Aβ oligomers is also thought to contribute to the mental decline in AD (Luscher and Huber, [@B56]). This appears to result from enhanced GluA2/GluA3-AMPAR endocytosis by Aβ oligomers (Jurado, [@B37]), which may require the participation of PICK1 (protein interacting with C kinase 1; Alfonso et al., [@B1]). Of particular note, Aβ-induced synaptic removal of AMPAR *via* endocytosis is necessary and sufficient to induce spine loss (Hsieh et al., [@B31]), which is in line with the role of GluA2-AMPAR in promoting dendritic spine formation and growth in cultured hippocampal neurons (Saglietti et al., [@B79]). This suggests that the dysregulation of AMPAR trafficking may have both adverse functional and structural consequences. Moreover, overexpression of the amyloid-precursor protein (APP) or exposure to Aβ oligomers resulted in abnormal enhancement of AMPAR surface diffusion *via* the activation of GluN2B-containing NMDARs (Opazo et al., [@B72]). Immobilizing AMPARs by crosslinking methods fully rescued spine loss induced by oligomeric Aβ (Opazo et al., [@B72]). These lines of evidence suggest that targeting of AMPAR trafficking may represent a new therapeutic avenue in AD and HD.

Parkinson's Disease (PD) {#s1-8}
------------------------

Parkinson's disease (PD) is another neurodegenerative disorder associated with loss of dopaminergic neurons of the substantia nigra projection to the striatum, of major importance for motor control. The cause of PD is unknown but is believed to involve both genetic and environmental factors (Kalia and Lang, [@B39]). PD is not only characterized by motor symptoms but also non-motor symptoms, including cognitive impairment (Bernal-Pacheco et al., [@B3]; Modugno et al., [@B68]). The cognitive decline and dementia in PD have been associated with hippocampal dysfunction (Svenningsson et al., [@B88]; Calabresi et al., [@B9]; Cosgrove et al., [@B18]). For example, mutations in PD-associated E3 ubiquitin ligase Parkin have been associated with juvenile-onset PD. Parkin regulates synaptic AMPAR endocytosis *via* its binding and retention of the postsynaptic scaffold protein, homer (Cortese et al., [@B17]; Zhu et al., [@B109]). The four common Parkin point mutations (T240M, R275W, R334C, G430D; Zhu et al., [@B109]) or Parkin knock-down (Cortese et al., [@B17]) impaired this capacity, reduced surface expression of GluA1- and GluA2-AMPARs, and disrupted glutamatergic synaptic transmission in hippocampal neurons. It should be noted that Parkin is primarily involved in mitochondrial homeostasis (McWilliams and Muqit, [@B66]). Mitochondria, as energy centers and calcium buffer organelles, may play an important role in the regulation of synaptic plasticity (Todorova and Blokland, [@B91]). Moreover, PD dementia is considered a convergence of α-synuclein, tau, and Aβ pathologies (Irwin et al., [@B36]; Shrivastava et al., [@B85]). As discussed in the AD section, both tau and Aβ appear to be involved in the removal of synaptic AMPARs (Jurado, [@B37]; Li et al., [@B50]; Shrivastava et al., [@B85]). Thus, PD-related dementia might involve dysregulation of AMPAR trafficking induced by Aβ and tau.

In addition to PD dementia, the motor deficits of PD have also been partially attributed to aberrations in AMPAR plasticity. There is an imbalance in glutamatergic signaling between the direct pathway spiny projection neurons (dSPNs) and indirect pathway SPNs (iSPNs), with LTP (hyper AMPAR signaling) found in iSPNs while LTD (hypo AMPAR signaling) found in dSPNs (Shen et al., [@B83]; Fieblinger et al., [@B20]; Shields et al., [@B84]). In general, activity in the direct-pathway neurons would promote appropriate actions while the indirect-pathway suppresses unnecessary actions or movements. Potentiation or loss of inhibition in the indirect-pathway is thought to contribute to motor dysfunction (Luscher and Huber, [@B56]; Shields et al., [@B84]). In support of this idea, the AMPAR antagonist, YM90K, was specifically delivered to the indirect-pathway through the DART (drugs acutely restricted by tethering) technique, that used HaloTag to capture and tether drugs to the cell surface. The treatment profoundly ameliorated motor deficits, such as akinesia in PD animal models (Shields et al., [@B84]).

Fragile X Syndrome (FXS) {#s1-9}
------------------------

Fragile X syndrome (FXS) is a neurodevelopmental disorder. It is the most common inherited cause of intellectual disability and a prevalent genetic cause of autism spectrum disorder (ASD; Cheng et al., [@B12]). FXS results from loss-of-function mutations in fragile X mental retardation protein (FMRP), an RNA-binding protein that regulates local translation of a subset of mRNAs at both presynaptic and postsynaptic locations in response to mGluR activation (Luscher and Huber, [@B56]). One primary consequence of FMRP loss is the enhancement of mGluR-LTD, which depends on GluA1-AMPAR endocytosis (Luscher and Huber, [@B56]; Cheng et al., [@B12]). *Fmr*1 knockout mice exhibit enhancement of mGluR-LTD both in the cerebellum and hippocampus (Luscher and Huber, [@B56]). Various mGluR5 antagonists have entered clinical trials (Berry-Kravis et al., [@B4]). This strategy aims at normalizing multiple cellular processes including LTD by targeting mGluRs rather than by directly interfering with ionotropic glutamate receptors, which have crucial physiological functions. However, the clinical efficacy of mGluR5 antagonists remains to be determined.

Impaired LTP in *Fmr*1 knockout mice has also been reported in multiple brain regions, such as the hippocampus (Lauterborn et al., [@B46]; Hu et al., [@B32]), anterior piriform cortex (Larson et al., [@B45]), deep-layer visual neocortex (Wilson and Cox, [@B101]), and ACC (Zhao et al., [@B107]; Wang et al., [@B99]). Restoring the synaptic delivery of GluA1-containing AMPARs by enhancing Ras-PI3K-Akt signaling rescued LTP in *Fmr1* KO mice (Hu et al., [@B32]; Lim et al., [@B51]). This indicates that targeting of AMPAR trafficking may be a potential therapeutic strategy in FXS.

Summary of AD, HD, PD, and FXS Models {#s1-10}
-------------------------------------

Taken together, the impairment in hippocampal or cortical LTP or the enhancement in LTD has been associated with behavioral and cognitive deficits in animal models of AD, HD, PD, and FXS ([Figure 1](#F1){ref-type="fig"}, bottom right panel). Enhancing AMPAR diffusion trapping mechanisms (such as with tianeptine), blocking endocytosis (such as with mGluR5 antagonists), or enhancing AMPAR function (such as with AMPAR positive allosteric modulators) have exhibited therapeutic effects, such as reversal of synaptic plasticity and memory defects in animal models of AD, HD and FXS. However, the effects of these strategies in human patients remain to be determined. Brain region- and AMPAR subunit-specific treatment is needed.

Discussion {#s2}
==========

While dysregulation of AMPAR synaptic plasticity is emerging as a point of convergence in multiple pathological pathways across several brain disorders, it is unlikely to be the major driver of pathology. Indeed, each brain disorder has a distinct and complex etiology and pathogenesis. Rather, the pathological impact on the excitatory synapse directly influences the expression of the disorders or associated symptoms, and these effects are reversible. Targeting a converging point of multiple pathological pathways, especially in early stages of diseases, such as HD and AD, may be more efficient than targeting any individual pathway. In addition, the pathological potentiation and weakening of synaptic strength both adversely impact the plastic range of the synapse and thus may hamper further plasticity (metaplasticity). Therefore, strategies that can preserve the plastic range of the synapse, eg. regulating AMPAR trafficking, will be beneficial. In particular, modulating AMPAR trafficking leads to AMPAR redistribution without perturbing AMPAR function, which is a great advantage.

Small interfering peptides that target protein-protein interactions are attracting increasing attention as potential therapeutics, partly due to their high binding specificity and affinity, and minimal off-target effects (Fosgerau and Hoffmann, [@B21]; Havasi et al., [@B28]). Interfering peptides targeting AMPAR endocytosis were shown effective in preventing the expression of D-amphetamine-induced behavioral sensitization and facilitating the extinction of morphine-induced conditioned place preference in rodent models of drug addiction (Brebner et al., [@B8]; Dias et al., [@B19]). We propose that peptides disrupting the diffusion trapping mechanism of AMPARs are an alternative strategy. Though promising, the therapeutic application of cell-penetrating peptides in humans remains challenging (Fosgerau and Hoffmann, [@B21]; Havasi et al., [@B28]). As an alternative, aptamers are oligonucleotide molecules that bind to a specific target molecule. For example, attempts have made to design RNA aptamers as AMPAR antagonists (Huang and Niu, [@B35]). However, there is still a long way to go to translate them into drug options.

A better understanding of the molecular mechanism and dynamics of AMPAR-mediated plasticity may help in the further identification of therapeutic targets. For dissecting mechanisms, the use of light-sensitive proteins allows fast and reversible manipulation of protein targets with high spatial-temporal precision (Paoletti et al., [@B73]). The development of optogenetic and optopharmacological tools may help to elucidate the spatial-temporal regulation of AMPAR trafficking in specific cell types and circuits in animal models. For example, genetically-encoded protein photosensors such as LOVTRAP and dimeric Dronpa, have been recently developed (Wang et al., [@B98]; Zhou et al., [@B108]). LOVTRAP can be used for reversible light-induced protein dissociation. It requires attaching one of the Zdk/LOV2 pairs to the target protein, and the other to the membrane (Wang and Hahn, [@B97]). Thus, LOVTRAP technology could serve to manipulate the synaptic anchoring of AMPARs by controlling the interaction between a membrane TARP and a PDZ-containing protein in the PSD. Another example is Dronpa, a reversibly photoswitchable fluorescent protein, which associates and dissociates in response to 400 nm and 500 nm illumination, respectively (Zhou et al., [@B108]). A generalizable method for optical control of kinases has been recently reported. Photoswitchable kinases, such as psRaf1, psMEK1, psMEK2, and psCDK5, have been successfully generated by attaching two photoswitchable dimeric Dronpa (pdDronpa) domains in the kinase functional domain. The light switch enables the caging and uncaging of the core kinase domain with high temporal and spatial precision (Zhou et al., [@B108]). This method could be used to elucidate local, synaptic regulation of AMPARs by protein kinases. Furthermore, a study successfully used a freely diffusible photoswitchable quinoxaline-2,3-dione, an antagonist selective for AMPARs, to control action potential firing optically (Barber et al., [@B2]). Another study developed a technique to inactivate synaptic GluA1 AMPARs *in vivo* using chromophore-assisted light inactivation and erased acquired fear memory in the animals (Takemoto et al., [@B89]). Thus, optogenetics and optopharmacology emerge as powerful tools for manipulating and interrogating synaptic plasticity with high spatial-temporal precision. Because light does not penetrate tissue easily, applying optogenetic tools in living animals often requires the implantation of invasive optical fibers into the brain. This has limited their applications in humans. Recently, an ultra-sensitive light-responsive molecule, SOUL, has been developed. Once engineered in the neurons inside the brain of mice and monkeys, the neurons can be turned on and off by illumination from outside of the head (Gong et al., [@B25]). Such non-invasive approaches hold promise for therapeutic optogenetics.
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